SEC Form 4 · accession 0000899243-19-007264
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
Mar 11, 2019
Accepted (ET)
Mar 12, 2019 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Mar 11, 2019 | G | 24,045 | $0.00 | D | 107,562 | D | |
| Common Shares | Mar 11, 2019 | G | 17,337 | $0.00 | A | 114,403 | I | By Spouse |
| Common SharesF2 | holding | — | — | — | 30,348 | I | By Genworks Inc. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F16,708 of the shares were gifted to family members that do not share the reporting person's household.
- F2Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.